Table 1.

Annual disease burden, mortality, and economic burden of current global strategy, idealized WHO preventive chemotherapy guidelines, and cost-effective preventive chemotherapy guidelines for schistosomiasis and STH

Strategy	Disease burden (DALYs)	Mortality (DALYs)	Economic lossesc (2015 US$, thousands)
No treatment	4,156,306	176,393	6,482,613
Current global strategya	3,957,325	176,392	6,182,450
Idealized WHO guidelinesb	3,474,731	159,921	5,462,829
Cost-effective guidelines18	1,674,551	88,877	2,715,934

Cost-effective guidelines18 relative to:	Avertable disease burden (DALYs)	Avertable mortality (DALYs)	Avertable economic lossesc (2015 US$, thousands)
No treatment	2,481,755	87,516	3,766,679
Current global strategya	2,282,774	87,515	3,466,516
Idealized WHO guidelinesb	1,800,180	71,044	2,746,895

^aEstimation based on WHO guidelines with current global coverage for preventive chemotherapy.

^bEstimation based on WHO guidelines with 75% coverage and uses school-based preventive chemotherapy programmes, except for inclusion of preschool-aged children in STH treatment. This reflects the stated priority within guidelines, the current global strategy, and empirical coverage estimated amongst different age groups. However, WHO guidelines do recommend treatment of women of childbearing age for STH, and treatment in entire communities under some circumstances above 50% prevalence for schistosomiasis, although coverage remains minimal in these groups.

^cEconomic losses are estimated as the product of disability (DALYs) and country GDP per capita (see Appendix).

Note: Results are annualized over a 5-year simulation and are intended to give a broad estimate of the magnitude of avertable health and economic loss. Methodological details, limitations, and discussions of uncertainty are provided in the Appendix.